Myriad Genetics shareholders approve equity plan amendments, elect directors at 2026 annual meeting

Proposal No. 4: Approval of the Proposed Amendment to the Amended and Restated 2012 Employee Stock Purchase Plan Votes Votes Votes Broker For Against Abstained Non-Votes 61,812,338 650,741 40,241 15,255,311 The stockholders voted to approve the proposed amendment to the Purchase Plan to increase the aggregate number of shares of common stock available for issuance under the Purchase Plan by an additional 4,000,000 shares.

Proposal No. 2: Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Year Ending December 31, 2026 Votes Votes Votes For Against Abstained 76,302,595 1,391,172 64,864 The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 was approved by stockholders.

Proposal No. 1: Election of Directors Votes Votes Votes Broker For Against Abstained Non-Votes Paul M. Bisaro 61,842,900 637,156 23,264 15,255,311 Rashmi Kumar 60,399,633 2,071,375 32,312 15,255,311 Lee N. Newcomer, M.D 61,576,936 894,837 31,547 15,255,311 Each of Paul M. Bisaro, Rashmi Kumar, and Lee N. Newcomer, M.D. was elected to serve as a Class III director of the Company for a term expiring at the 2029 Annual Meeting of Stockholders, and until his or her successor is duly elected and qualified or until his or her earlier death, resignation, retirement or removal.

Proposal No. 3: Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement Votes Votes Votes Broker For Against Abstained Non-Votes 59,356,710 3,098,966 47,644 15,255,311 The advisory vote to approve the compensation of the Company's named executive officers, as disclosed in the proxy statement, was approved by stockholders.

Proposal No. 5: Approval of the Proposed 2026 Employee, Director and Consultant Equity Incentive Plan Votes Votes Votes Broker For Against Abstained Non-Votes 59,389,193 3,066,087 48,040 15,255,311 The stockholders voted to approve the 2026 Plan.